Proteon Therapeutics Slumps On Phase III Study Miss In CKD
Executive Summary
Shares in Proteon Therapeutics lost nearly three-quarters of their value on news that its first Phase III trial for its lead product vonapanitase had failed. Undeterred, however, the company is increasing the size of its second pivotal study on the back of positive data from certain key endpoints.
You may also be interested in...
Expedited Review Pathways: Three More Breakthroughs, Third RMAT Awarded
US FDA's popular breakthrough therapy designation given to Proteon's vonapanitase for dialysis patients, Synthetic Biologics' ribaxamase to prevent C. difficile infection, and River Vision's teprotumumab for thyroid eye disease; Vericel's cell therapy for heart failure is designated a regenerative medicine advanced therapy.
Proteon plans Ph III for elastase in kidney disease surgery
Proteon Therapeutics is planning to move its recombinant human elastase into Phase III trials after announcing positive results from a Phase II trial of the product, PRT-201, in chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF) in preparation for hemodialysis.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.